Ocuphire Pharma, Inc. Quarterly report pursuant to Section 13 or 15(d)

Warrants (Schedule Of Unrealized Gain/(Loss) On Fair Value Of Warrants) (Details)

Warrants (Schedule Of Unrealized Gain/(Loss) On Fair Value Of Warrants) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Class of Warrant or Right [Line Items]
Unrealized (loss) gain on fair value of warrants	$ (17,689,580)	$ 855,955
Expired Warrants [Member]
Class of Warrant or Right [Line Items]
Unrealized (loss) gain on fair value of warrants		1,821
December 2012 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Unrealized (loss) gain on fair value of warrants	(42,721)	1,368
July 2013 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Unrealized (loss) gain on fair value of warrants	(549,380)	30,654
October 2013 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Unrealized (loss) gain on fair value of warrants	(677,210)	26,440
January 2014 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Unrealized (loss) gain on fair value of warrants	(1,081,810)	25,286
November 2015 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Unrealized (loss) gain on fair value of warrants	(4,119,750)	328,713
November 2015 Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Unrealized (loss) gain on fair value of warrants	(271,825)	21,882
March 2016 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Unrealized (loss) gain on fair value of warrants	(3,932,511)	392,145
March 2016 Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Unrealized (loss) gain on fair value of warrants	(269,032)	$ 27,646
September 2016 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Unrealized (loss) gain on fair value of warrants	(6,242,191)
September 2016 Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Unrealized (loss) gain on fair value of warrants	$ (503,150)